Health

FDA Rejects Closely Watched Lung Cancer Drug From China

The Food and Drug Administration has rejected a first-of-its-kind cancer drug invented in China, marking a significant setback for a medicine that had emerged as a symbol of China’s growing prominence in pharmaceutical development.

Summit Therapeutics, a Florida-based company attempting to introduce the drug to the American market, revealed the regulatory decision in a news release issued on Sunday. Summit previously acquired the U.S. rights to the medication from Akeso Biopharma, the Chinese drugmaker that originally developed the treatment in its laboratories and currently sells it in China.

Summit had sought approval specifically for designated patients suffering from advanced lung cancer. The medication had previously generated high expectations because clinical testing is underway for a broader range of malignancies, encompassing colon, bladder, and breast tumors.

According to Sunday’s announcement, the FDA informed Summit that the application was denied because the global clinical trial underpinning the request failed to demonstrate a statistically significant benefit in extending patient survival.

Summit’s regulatory bid relied on findings from a clinical study conducted across the United States, Canada, Europe, and Asia, which enrolled patients who had previously undergone targeted therapy. The trial evaluated patients who received a combination of ivonescimab and chemotherapy against a control group treated exclusively with chemotherapy. While that study demonstrated success in delaying cancer progression, it fell short of the survival threshold required by regulators.

Summit contended that the failure to extend patient lives was attributable to slow enrollment rates during the study. In an effort to strengthen its regulatory submission, the company provided the FDA with post-hoc analyses of longer-term patient outcomes that were not originally outlined in the formal research plan, though those additional evaluations proved insufficient to sway regulators.

Evelyn Price

Evelyn Price covers health news, medical research, public health developments, and wellness topics. She aims to present evidence-based information in clear language, helping readers understand important studies, health policies, and advances in medicine.
Back to top button